TITLE

ALIMERA SUBMITS ILUVIEN NDA FOR DIABETIC MACULAR EDMA

PUB. DATE
August 2010
SOURCE
Worldwide Biotech;Aug2010, Vol. 22 Issue 8, p6
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on a new drug application (NDA) submitted by Alimera Sciences Inc. to the U.S. Food and Drug Administration (FDA) for its Iluvien flucocinolone acetonide intravitreal insert for diabetic macular edema (DME) treatment. A priority review is being requested by the company, which may prompt the FDA to release an action letter in the fourth quarter of 2010. According to Dan Myers, president and chief executive officer (CEO) of Alimera, Iluvien will serve as an alternative to the traditional multiple corticosteroid injections.
ACCESSION #
52570946

 

Related Articles

  • pSivida Corp. Reports Alimera's Intention to Resubmit Application to FDA for ILUVIEN(r) in DME Using Data from Completed Trials.  // Biomedical Market Newsletter;8/7/2012, Vol. 21, p1 

    The article offers information on the plans of Alimera Sciences Inc. related with resubmission of drug application to the U.S. Food and Drug Administration (FDA) for approval of the drug, Iluvien in treatment of diabetic macular edema (DME). Several issues have been raised by the FDA on phase...

  • Alimera resubmits NDA for intravitreal insert.  // Ophthalmology Times;6/1/2011, Vol. 36 Issue 11, p3 

    The article reports on Alimera Sciences Inc.'s resubmission of the new drug application (NDA) for an investigational intravitreal insert containing fluocinolone acetone (Iluvien) to the U.S. Food and Drug Administration (FDA).

  • FDA Seeks More Data on Iluvien Studies.  // Review of Ophthalmology;Feb2011, Vol. 18 Issue 2, p7 

    The article reports on the Complete Response Letter (CRL) received by Alimera Sciences Inc. from the U.S. Food and Drug Administration regarding Alimera's New Drug Application for the investigational drug Iluvien.

  • Alimera Moves Forward With Iluvien Review.  // Review of Ophthalmology;May2014, Vol. 21 Issue 5, p9 

    The article reports that the drug firm Alimera Sciences Inc. has resubmitted the New Drug Application (NDA) for Iluvien, a treatment for Diabetic Macular Edema (DME), to the U.S. Food and Drug Administration (FDA) for review, as of May 2014 and presents views of Dan Myers of Alimera on the NDA.

  • pSivida Announces Resubmission of New Drug Application for ILUVIEN(r).  // Biomedical Market Newsletter;5/16/2011, p63 

    The article focuses on the May 13, 2011 announcement by pSivida Corp. regarding the resubmission by its licensee, Alimera Sciences Inc., of a drug application for Iluvien (r), a drug for diabetic macular edema (DME), to the U.S. Food and Drug Administration (FDA). According to Alimera, the...

  • FDA seeks more data for FA insert. Groves, Nancy // Ophthalmology Times;12/1/2011, Vol. 36 Issue 23, p1 

    The article reports on the delay of the approval of Alimera Sciences Inc.'s investigational fluocinolone acetonide (FA) intravitreal insert (Iluvien) by the U.S. Food Drug Administration (FDA). It states that the drug is developed to treat diabetic macular edema (DME) associated with diabetic...

  • Other News To Note.  // BioWorld Today;10/21/2013, Vol. 24 Issue 202, p3 

    This section offers news briefs on the pharmaceutical industry. Alimera Sciences Incorporated of Atlanta, Georgia has received its third complete response letter from the U.S. Food and Drug Administration (FDA) for the drug application for Iluvien. Avexis Incorporated and Biolife Science Limited...

  • FDA delays DME insert approval. Webb, Jennifer A. // Ophthalmology Times;1/15/2011, Vol. 36 Issue 2, p1 

    The article focuses on the additional data requested by the U.S. Food and Drug Administration (FDA) from Alimera Sciences Inc. for the approval of its investigational sustained drug-delivery system fluocinolone acetonide intravitreal insert or Iluvien. The FDA has requested for safety and...

  • Kalbitor for HAE attacks.  // Monthly Prescribing Reference;Jan2010, Vol. 26 Issue 1, pA12 

    The article reports on the approval of the drug Kalbitor from Dyax Corp. as treatment for acute attacks of hereditary angioedema (HAE) by the U.S. Food and Drug Administration (FDA).

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics